GlassScriptPhysician profile
Patrick Yudez
NPI 1366152126
$6,139.48
in general payments reported to CMS, 2019-2025
34 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.63 · 2023: $2,390 · 2024: $3,536 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,118.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $565.76 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $500.21 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $491.17 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $484.16 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $454.23 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.66 | 2023-2024 | Jardiance |
| Radius Health, INC. | $382.17 | 2023-2024 | Tymlos |
| Alexion Pharmaceuticals, INC. | $367.10 | 2023-2024 | Strensiq |
| Mannkind Corporation | $321.52 | 2023-2024 | Afrezza |
| Amgen INC. | $254.15 | 2024-2025 | Tepezza, Evenity, Prolia |
| Abbvie INC. | $237.03 | 2023-2024 | |
| Recordati_rare_diseases_inc. | $215.46 | 2023-2024 | Signifor Lar, Isturisa |
| Almatica Pharma LLC | $176.20 | 2024 | Teriparatide |
| Kyowa Kirin, INC. | $173.22 | 2023-2025 | Crysvita |
| Ibsa Pharma INC. | $150.04 | 2023-2024 | Tirosint, Licart, Tirosint |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $136.69 | 2023-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $115.76 | 2023-2025 | Korlym |
| Amphastar Pharmaceuticals, INC. | $96.01 | 2024 | |
| Esperion Therapeutics, INC. | $77.91 | 2023-2024 | Nexletol |
| Averitas Pharma INC. | $75.85 | 2023-2024 | Qutenza |
| Novartis Pharmaceuticals Corporation | $58.44 | 2024-2025 | |
| Daiichi Sankyo INC. | $56.76 | 2024-2025 | Injectafer |
| Ascensia Diabetes Care US INC. | $49.65 | 2023-2024 | |
| Pfizer INC. | $33.44 | 2023 | |
| Neurocrine Biosciences, INC. | $31.01 | 2024 | |
| Astellas Pharma US INC | $30.34 | 2024 | Veozah |
| Tolmar, INC. | $30.01 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $29.16 | 2024 | Imcivree |
| Antares Pharma, INC. | $27.07 | 2024 | Xyosted |
| Astrazeneca Pharmaceuticals LP | $26.81 | 2024 | Lokelma |
| Takeda Pharmaceuticals U.S.A., INC. | $25.58 | 2024 | Vpriv |
| Ascendis Pharma Endocrinology INC | $24.23 | 2024 | |
| Medtronic, INC. | $20.42 | 2024 | Minimed 780g |
| Chiesi USA, INC. | $15.26 | 2024 | Mycapssa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Yudez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.